Recorded at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with BioAge co-founder and CEO Kristen Fortney on aging biology, inflammation and why BioAge believes its oral NLRP3 inhibitor could have applications across multiple diseases.